Roche Holding AG's acquisition of 89bio, Inc. to expand cardiometabolic offerings and drive growth beyond GLP-1. Click for ...

Roche acquires 89bio for up to $3.5B, betting on pegozafermin for MASH. Click here to read the latest analysis on ETNB and ...

Massachusetts voters overwhelmingly banned the use of Massachusetts Comprehensive Assessment Systems as a graduation in a referendum question in November 2024. The state has left it up to individual ...

Entera Bio Ltd. ENTX recently reported encouraging pharmacokinetic data, underscoring the potential of its first-in-class oral GLP-2 analog therapy for patients with short bowel syndrome (SBS). The ...

Roche has agreed to buy U.S. biotech firm 89bio for up to $3.5 billion, joining a race to offer new liver disease treatments that complement an intense push in the area of weight-loss drugs. The deal ...

Metabolic Dysfunction-Associated Steatohepatitis (MASH), one of the most prevalent comorbidities of obesityAcquisition supports Roche’s strategy as it enhances the company’s portfolio in ...

The NT has assembled a young and exciting group of riders keen to take on the challenge of the MXGP and show their stuff on ...

These hilarious but underrated sitcoms deserve a spot in your rewatch rotation, from Happy Endings to Superstore.

Prepare for your ICSE Class 9 Chemistry half-yearly exams with 2025 sample paper. Practice with a realistic test simulation, identify weak areas, and master time management. Download the PDF with a ...

As a data science student, Jennifer treats her hobbies like an experiment, where failure is an important part of the learning process. She also loves running, playing ultimate frisbee and learning to ...

Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion - ...

Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion - - Transaction reflects the potential of Tourmaline's pacibekitug, a long-acting ...